-
- Kirino Eiji
- Department of Psychiatry, Juntendo University Shizuoka Hospital Department of Psychiatry, Juntendo University School of Medicine Juntendo Institute of Mental Health
この論文をさがす
抄録
Purpose: We administered olanzapine to 24 outpatients with bipolar disorder who had experienced a depressive or mixed episode as their most recent episode to evaluate the efficacy and safety of olanzapine in clinical practice.<br>Methods: The duration of study treatment was 8 weeks. Symptoms in each subject were assessed using the Montgomery Åsberg Depression Rating Scale (MADRS) and the Clinical Global Impressions-Severity of Illness, Bipolar Version (CGI-BP) at the start of treatment with olanzapine and at Week 4 and Week 8 of treatment.<br>Results: A total of 17 subjects underwent the assessments at Week 4, and 13 subjects completed the 8-week treatment regimen and the assessments at Week 8. The mean total score and each individual item score of the MADRS were significantly improved at Week 4 and Week 8 compared to those at the start of treatment. The mean CGI-BP Depression and CGI-BP Overall scores were significantly improved at Week 4 and Week 8, while the mean CGI-BP Mania score was not significantly different at Week 4 or Week 8 compared to that at the start of treatment. Adverse drug reactions were reported in 3 subjects during the study: hyperphagia in 2 subjects and light-headed feeling in 1 subject. No manic switches were observed.<br>Discussion: The results of this study confirmed the efficacy and safety of olanzapine in outpatients with bipolar depression in clinical practice.
収録刊行物
-
- Clinical Neuropsychopharmacology and Therapeutics
-
Clinical Neuropsychopharmacology and Therapeutics 5 (0), 11-17, 2014
日本臨床精神神経薬理学会
- Tweet
キーワード
詳細情報 詳細情報について
-
- CRID
- 1390001205338099200
-
- NII論文ID
- 130003395575
-
- ISSN
- 18848826
-
- 本文言語コード
- en
-
- データソース種別
-
- JaLC
- Crossref
- CiNii Articles
-
- 抄録ライセンスフラグ
- 使用不可